Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selcia Granted Patent for CEfrag™ Drug Discovery Platform

Published: Friday, September 21, 2012
Last Updated: Friday, September 21, 2012
Bookmark and Share
CEfrag™ platform uses capillary electrophoresis to identify fragment compounds.

Selcia Limited has been granted a UK patent for the technology platform underpinning the company’s CEfrag™ drug screening service.

Titled “Capillary electrophoresis method for assessing the binding of chemical compounds to biological targets”, the patent relates to the screening of compound libraries against specific targets, in particular screening for weak-binding ligands.

Numbered GB 2481168, the patent was filed 20 September 2010 and granted 27 June 2012.

The patenting of Selcia’s CEfrag technology is the culmination of a three year plan by Selcia to build a fully integrated drug discovery division alongside its existing 14C radiochemistry service.

The newly patented technology was first unveiled by Selcia following the acquisition of IP and expertise from Cetek Corporation in 2009.

Further technical development of the fragment screening platform resulted in the launch of CEfrag the following year with a fragment library of 1,500 compounds.

CEfrag has generated a great deal of interest amongst pharmaceutical and biotech organizations and this has already resulted in a number of collaborations including a recent deal with Heptares, a UK-based biotech company that discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors) The goal of this collaboration was to identify fragment ligands that specifically bind to a Heptares GPCR drug target.

Selcia’s CEfrag™ platform uses capillary electrophoresis to identify fragment compounds that selectively bind to drug targets.

A significant advantage of this approach is that all reagents are in solution and no tethering of the protein is required, enabling near physiological ligand/target interactions to be observed with a low false positive rate.

The technology can be used to detect fragment/target interactions across a wide range of target classes including “challenging” targets such as protein-protein interactions.

The technology can also be used to screen natural extracts for novel druggable natural compound starting points for drug discovery programmes, an area in which Selcia specializes.

Simon Bury, Business Development Director - Discovery, Selcia, comments: “The CEfrag drug screening platform has already shown itself to be a novel, scientifically robust approach to drug discovery. By patenting the technology we have demonstrated our strong intent to build a differentiated technology platform that will sit at the heart of Selcia’s integrated drug discovery service capabilities”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selcia Appoints New Director of Discovery
Appointment of John Davis to the role of Director of Discovery.
Wednesday, October 09, 2013
Selcia and Heptares Therapeutics Announce New Fragment Screening Collaboration
Partnership to utilize Selcia’s CEfrag™ capillary electrophoresis fragment screening technology.
Thursday, April 19, 2012
Scientific News
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Antarctic Sponge Extract Kills MRSA
New findings may provide opportunity for developing new drugs to fight dangerous bacteria currently highly resistant to treatment.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!